Tag Archives: blockbuster

Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster

When Amgen signed an outcomes-based reimbursement deal for its blockbuster rheumatoid arthritis drug Enbrel with Harvard Pilgrim Healthcare in 2017, it seemed like a strategy for preserving the market share of a product on the cusp of losing its patent protection. The patent threat has since been pushed off several years—but Amgen is still making… Read More »